JF DiJoseph, MM Dougher, DC Armellino, DY Evans and NK Damle Oncology Discovery Research, Wyeth Research, Pearl River, NY, USA CMC-544 (inotuzumab ozogamicin) is a CD22-specific cytotoxic immunoconjugate of calicheamicin intended for the treatment of B-lymphoid malignancies. This preclinical study investigated antitumor activity of CMC-544 against CD22 þ acute lymphoblastic leukemia (ALL). CMC-544 inhibited in vitro growth of ALL cell lines more potently than that of Ramos B-lymphoma cells. When administered to nude mice with established sc xenografts of REH ALL, CMC-544 caused dose-dependent inhibition of xenograft growth producing complete tumor regression and cures in tumor-bearing mice at the highest dose of 160 lg/kg of conjugated calicheamicin. In contrast, a nonbinding control conjugate was 16-fold less effective than CMC-544 in inhibiting growth of REH ALL xenografts. When REH cells were injected intravenously in scid mice and allowed to disseminate systemically, mice developed hind-limb paralysis that was effectively prevented by treatment with CMC-544. Flow cytometric analysis of cells recovered from the bone marrow from mice with disseminated disease verified the presence of engrafted ALL cells. Significantly reduced numbers of ALL cells were recovered from the bone marrow of CMC-544-treated mice than from vehicle-treated mice with disseminated disease. The anti-leukemia activity of CMC-544 demonstrated here further supports clinical evaluation of CMC-544 for the treatment of CD22 þ leukemia.
Introduction
There are approximately 15 000 new cases of acute lymphoblastic leukemia (ALL) diagnosed each year in the industrialized nations 1 of which 85% are derived from cells committed to the B-cell lineage (pre-B-or B-ALL).
2 ALL represents the fifth most common type of childhood cancer.
3-5 While combination chemotherapeutic strategies involving cytotoxic drugs such as cyclophosphamide, cytarabine, daunorubicin and vincristine provide cure rates approaching 80-90% in pediatric ALL patients and 40% in adult ALL patients, 1 the remaining ALL patients experience disease relapse. One of the principal limitations in repeatedly treating ALL patients in relapse with combination chemotherapy is the patients' susceptibility to the dose-limiting side effects of the current treatment regimens necessitating new treatment modalities.
Antibody-targeted chemotherapy using immunoconjugates of calicheamicin is one such strategy that has been clinically validated in acute myeloid leukemia by gemtuzumab ozogamicin (Mylotarg or CMA-676). This strategy employs tumor celltargeted delivery of a derivative of a potent DNA-damaging cytotoxic natural product, calicheamicin, via its covalent linkage to the targeting antibody. Gemtuzumab ozogamicin is an immunoconjugate of N-acetyl g-calicheamicin dimethyl hydrazide (CalichDMH) and is targeted to human CD33, a myeloid lineage-specific antigen. 6 Gemtuzumab ozogamicin is approved in the United States and Japan for clinical use as a monotherapy in elderly acute myeloid leukemia (AML) patients in first relapse. 7 It has demonstrated a favorable safety profile in relapsed AML patients and is being evaluated in combination with conventional chemotherapy as a first-line treatment option. 8 Inotuzumab ozogamicin (CMC-544) is a CD22-targeted immunoconjugate of CalichDMH that is currently being evaluated in phase I clinical trials in patients with nonHodgkin's B-cell lymphoma and has demonstrated significant clinical activity in patients who had failed multiple therapies. 9, 10 Our previous studies demonstrated strong preclinical antitumor activity of CMC-544 against multiple subcutaneous 11 or systemically disseminated human CD22 þ B-cell lymphoma xenografts.
12 ALL blast cells differentially express a number of distinct B-lymphoid-or myeloid lineage-specific antigens including CD19, CD20, CD22, CD33 and CD52 [13] [14] [15] and expression of these antigens provides the opportunity to apply antibody-based therapeutic strategies. 16 The use of antibodies for the tumor-targeted delivery of potent cytotoxic agents such as calicheamicin may overcome the limitations imposed by the side effects from nontargeted delivery of chemotherapeutic agents in ALL patients. In this context, a CD22-specific immunotoxin was shown to kill CD22 þ pre-B ALL cells in vitro. 17 Furthermore, CD22 expressed on ALL blasts was shown to be modulated and probably internalized when the anti-CD22mAb, epratuzumab, was administered to ALL patients. 18 CD22 expressed on ALL blasts may allow these cells to be targeted using newer therapeutic agents such as CMC-544.
In the present preclinical study, we evaluated the therapeutic potential of CMC-544 against human ALL and our results show that CMC-544 (inotuzumab ozogamicin) may be used as a therapeutic agent in the treatment of CD22 þ ALL.
Materials and methods

Cell lines
Human ALL cell lines, REH (CRL-8286), Sup-B15 (CRL-1929) and RS4;11 (CRL-1873), the Burkitt's B-lymphoma lines, Ramos (CRL-1923), Raji (CCL-86) and Daudi (CCL-213), B-cell nonHodgkin's lymphoma cell line, RL (CRL-2261) and a myeloid leukemic cell line, HL-60 (CCL-240) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cell lines were determined to be mycoplasma free as determined by a polymerase chain reaction mycoplasma detection assay (ATCC). The cell lines were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, 10 mM HEPES (N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid), 1 mM sodium pyruvate, 0.2% glucose, penicillin G sodium 100 U/ml, and streptomycin sulfate 100 mg/ml. Before use, viable cells were isolated by density-gradient centrifugation (30 min at 1000 g) using Lymphoprep (Nycomed, Oslo, Norway).
Mice
Female BALB/c nu/nu (nude) mice (18-23 g ) and male scid mice (CB17 scid, 20-25 g) were obtained from Charles River Laboratories (Wilmington, MA, USA). All procedures using mice were approved by the Wyeth Animal Care and Use Committee according to established guidelines.
Antibody conjugates
Human CD22-targeted CMC-544 is comprised of a humanized IgG4 anti-CD22mAb, G5/44, linked to N-acetyl g calicheamicin dimethyl hydrazide via an acid-labile AcBut linker with an average drug loading of 73 mg of CalichDMH per mg of G5/44 protein (approximately 6 mol/mol) and has been described. 11, 12 Human CD33-targeted CMA-676 is comprised of a humanized IgG4 anti-CD33mAb, hP67.6 and linked to CalichDMH via the acid-labile AcBut linker with an average drug loading of 35 mg of CalichDMH per mg of hP67.6 protein (3.2 mol/mol). All conjugates were confirmed as having low endotoxin (o5.0 EU/ml), as determined by the limulus amebocyte lysate test (BioWhittaker, Walkersville, MD, USA). Doses of calicheamicin conjugates are expressed as equivalents of CalichDMH and that of unconjugated antibody are expressed as the quantity of antibody protein.
Flow cytometry
Aliquots of 10 5 cells were suspended in 100 ml phosphatebuffered saline supplemented with 1% (v/v) bovine serum albumin (BSA). The cells were then incubated at 41C for 30 min with 10 mg/ml of polyclonal human IgG1 as a nonbinding control or primary antibody (G5/44, hP67.7 or rituximab). Binding of the primary antibody to the cells was flow cytometrically revealed by the binding of fluorescein isothyocyanate (FITC)-conjugated goat anti-human IgG antibody using FACSort flow cytometer (Becton Dickinson Immunocytometry Systems, Sunnyvale, CA, USA).
Bone marrow cells collected from mice were evaluated for the expression of human or murine CD45 antigen by incubating with control FITC-labeled rat IgG2A, FITC-labeled mouse IgG1, FITC-labeled rat anti-mouse CD45 or FITC-labeled mouse antihuman CD45 (all FITC-labeled reagents from BD Pharmingen, San Diego, CA, USA). Cells were pelleted, washed with phosphate-buffered saline (PBS)-1% BSA and then fixed with 1% formaldehyde. Samples were analyzed on a FACSort flow cytometer.
Growth inhibition studies
Effect of conjugated or unconjugated CalichDMH on ALL cells or B-lymphoma cells was assessed using a cellular viability indicator (MTS, Promega, Madison, WI, USA) to determine the number of surviving cells following exposure to various drug treatments. Cells were seeded in 96-well microtiter plates at a density of 5000-10 000 cells/well and exposed to various concentrations of CMC-544, CMA-676 or unconjugated CalichDMH. Following determination of the number of viable cells surviving 96 h of drug exposure, the IC 50 of each treatment was calculated based on the logistic regression parameters derived from the dose-response curves. IC 50 s were calculated by logistic nonlinear regression and are reported as the CalichDMH concentration (pM) from each treatment group that causes 50% loss of cell viability.
Subcutaneous BCL xenografts
Female, athymic nude mice were exposed to total body irradiation (400 rad) to further suppress their residual immune system and facilitate the establishment of xenografts. Three days later, mice were injected s.c. with 5 Â 10 6 REH ALL cells suspended in Matrigel (Collaborative Biomedical Products, Belford, MA, USA, diluted 1:1 in RPMI-1640 medium) in the right flank. Mice with staged tumors, 0.2 g (n ¼ 6-8 mice/ treatment group), were administered i.p. with normal saline (vehicle), CMC-544 or CMA-676 and the same treatment was repeated twice, 4 days apart (Q4D Â 3). Tumors were measured at least once a week and their mass (7s.e.m.) was calculated as described before. 11, 12 Tumor mass for each calicheamicin treatment group was compared to that from the vehicle-treated group for statistical significance using analysis of variance (ANOVA) and subsequent pairwise comparisons to the vehicletreated group using a one-tailed t-test ANOVA and subsequent pairwise comparisons to vehicle with the error term for the t-test based on the pooled variance across all treatment groups.
Assessment of antitumor efficacy against disseminated BCL
Male scid mice were injected intravenously (i.v.) with 3 Â 10 6 REH cells in the tail vein and the injected ALL cells were allowed to disseminate for 9 days. Mice with disseminated REH were administered i.p. with vehicle (PBS, n ¼ 9 mice/treatment group), or CMC-544 at either 4 or 80 mg of CalichDMH/kg (n ¼ 10) and these treatments were repeated twice 4 days apart (Q4D Â 3). Mice with disseminated ALL were monitored daily for the presence of hind-limb paralysis or death. Survival curves for the treatment groups were constructed using the KaplanMeier method.
In a separate study, four vehicle-treated mice exhibiting hindlimb paralysis were anesthetized and bled by cardiac puncture. The mice were then euthanized by CO 2 asphyxiation according to institutional regulations and mononuclear cells were isolated from the spleen and bone marrow (femur). Bone marrow cell suspensions were prepared by flushing both femurs with RPMI plus 10% fetal calf serum. Three CMC-544-treated mice that did not exhibit signs of hind-limb paralysis were also euthanized at similar time points as those of the vehicle-treated mice exhibiting hind-limb paralysis. The CMC-544-treated mice were bled by cardiac puncture along with collection of mononuclear cells as described above.
Results
Expression of CD22 on the surface of B-ALL cell lines
The expression of B-lymphoid lineage-specific antigens CD20 and CD22 and that of the myeloid lineage-specific antigen Targeted therapy of ALL with CMC-544 (inotuzumab ozogamicin) JF DiJoseph et al CD33 on the surface of three ALL cell lines, REH, RS4;11 and SUP-B15, and Ramos NHL line was examined by flow cytometry. As shown in Figure 1 , the surface expression of CD20 and CD22, while detectable, was significantly lower on REH and RS4;11 ALL cells than on Ramos B-lymphoma cells. The cell line SUP-B15 did not demonstrate readily detectable expression of CD20 or CD22. None of the cell lines expressed detectable levels of CD33. The expression of CD22 on ALL cell lines, REH and RS4;11, albeit lower than that on Ramos B cells, is consistent with their B-lymphoid origin. SUP-B15 cells have previously been characterized as pre-B ALL. 19 
Inhibition of ALL growth by calicheamicin immunoconjugates
The effect of CD22-specific CMC-544 and CD33-specific CMA-676 on the growth of ALL cell lines and Ramos NHL line was examined in 96 h in vitro culture assays. CMA-676 was used as an isotype-matched, nonbinding control conjugate. Unconjugated CalichDMH was also used to assess the sensitivity of these cell lines to calicheamicin. Ramos BCL lymphoma cells were used previously in the characterization of CMC-544. 11 As shown in Figure 2 , each of the three ALL cell lines exhibited greater sensitivity to CalichDMH than B-cell lymphoma cell lines or myeloid leukemic cell line HL-60.
11 CMC-544 exerted a 16-to 63-fold more potent growth inhibitory effect on each of the four cell lines than the nonbinding control CMA-676. In cell lines with readily detectable surface expression of CD22, the growth inhibitory effect of CMC-544 was 2-to 6-fold more potent than that of unconjugated CalichDMH.
Effect of CMC-544 on growth of subcutaneous REH xenografts
We examined the effect of CMC-544 on the growth of sc xenografts of REH ALL established in nude mice. CMC-544 was administered i.p. at 10, 40 or 160 mg/kg (Q4D Â 3) of conjugated CalichDMH to the tumor-bearing mice and its antitumor activity compared with that of vehicle (PBS) or CMA-676 (160 mg/kg of conjugated CalichDMH, Q4D Â 3). Both CMC-544 and CMA-676 significantly (Po0.05) inhibited tumor growth compared with vehicle-treated mice from day 20 onward (Figure 3 ). CMC-544 at a dose of 160 mg/kg caused 100% regression of tumor growth and all of the treated mice remained tumor-free throughout the observation period of 102 days and were thus considered cured. In the 40 mg/kg dose group, tumor growth was completely suppressed for approximately 60 days after which the tumors began to grow back. The lowest dose of CMC-544 (10 mg/kg) was effective in suppressing REH tumor growth for 30 days before regrowth of the tumors. The antitumor activity of isotype-matched nonbinding control conjugate, CMA-676, at the dose of 160 mg/kg, was 16-fold less potent than that of CMC-544. A mixture of unconjugated G5/44 (3 mg/kg) and unconjugated CalichDMH (160 mg/kg) when administered i.p. Q4D Â 3 was ineffective in inhibiting the growth of REH xenografts and was associated with treatment-related deaths of all (6/6) tumorbearing mice in this group. These results suggest that CMC-544 can provide potent antitumor therapeutic effect against B-ALL xenografts.
Assessment of antitumor efficacy of CMC-544 against disseminated disease
The ability of CMC-544 to protect scid mice against systemically disseminated REH ALL was examined. REH cells were previously demonstrated to disseminate throughout the body after i.v. injection in mice and cause hind-limb paralysis due to infiltration of the cells into the spinal cord. 20 CMC-544, administered at a dose of 80 mg/kg (Q4D Â 3) produced 100% survival of the mice over the entire 127-day observation period. At the dose of 4 mg/kg (Q4D Â 3), 90% of the mice survived throughout the observation period (Figure 4) . In contrast, the diseased mice in the vehicle-treated group succumbed to the disseminated disease with an average survival period of 55 days and, by day 77, all mice in this treatment group were killed. These results suggest that CMC-544 can protect mice with systemically disseminated ALL.
In a separate study, four vehicle-treated mice were killed when they initially exhibited hind-limb paralysis (days 35, 41, 41 and 43). At approximately equal time points (days 36, 41 and Targeted therapy of ALL with CMC-544 (inotuzumab ozogamicin) JF DiJoseph et al Discussion CD22 is a B-lymphoid-lineage-specific molecule that is expressed by a majority of patients with ALL. [13] [14] [15] Thus, CD22 þ ALL can be therapeutically targeted using antibodybased therapeutic agents. CMC-544 is a CD22-specific immunoconjugate of calicheamicin that exerts preferential cytotoxic effects against CD22 þ tumor targets. 11, 12 This study provides strong preclinical evidence of the antitumor efficacy of CMC-544 against subcutaneous xenografts and systemically disseminated form of CD22 þ ALL. This study also confirms our previous observations that CD22-mediated intracellular delivery of conjugated calicheamicin is more potent than that of unconjugated calicheamicin against CD22 þ malignant cells, 11 further exemplifying the therapeutic potential of tumor-targeted delivery of cytotoxic agents.
Calicheamicin is a DNA-damaging agent that binds DNA in the minor groove and, in a cellular thiol-dependent manner, brings about double-strand DNA breaks leading to G 2 /M arrest of cycling cells and subsequent cell death. 21 Zwaan et al.
22
demonstrated that primary ALL cells were more sensitive to the cytotoxic effects of calicheamicin than primary AML cells or normal bone marrow cells. The three ALL cell lines (REH, RS4;11 and SupB15) evaluated in this study demonstrated greater in vitro sensitivity to CalichDMH than Ramos Blymphoma cells. CD22-targeted CalichDMH was 2-to 5-fold more potent than untargeted CalichDMH in inhibiting growth of the CD22 þ ALL cell lines even though these cell lines expressed relatively low levels of CD22 (Figure 1 ). In contrast, Ramos Blymphoma cells expressed higher surface CD22 but were at least fivefold less sensitive to unconjugated CalichDMH than ALL cells. That CMC-544 was able to cause more potent growth inhibition of these CD22 þ cells than unconjugated CalichDMH is consistent with the CD22-mediated internalization of CMC-544 resulting in the efficient intracellular delivery of CalichDMH. The above observations made using ALL cell lines need to be further confirmed using leukemic blasts isolated from ALL patients to support the clinical use of CMC-544.
The increased sensitivity of ALL cells to CalichDMH was also apparent in the in vivo studies involving CD22 þ CD33 À ALL xenografts in which the nonbinding conjugate, CD33-specific CMA-676, caused significant inhibition of the growth of ALL xenografts. At the same dosage, CMA-676 was ineffective against B-lymphoma xenografts as shown previously.
11 Similar in vivo antitumor activity of antigen-nonspecific immunoconjugates of calicheamicin with an acid-labile linker using xenografts of calicheamicin-sensitive human carcinomas cell lines has been previously described by our group as a reflection of passive targeting. 23 The in vivo efficacy of CMC-544 in the ALL xenograft model was 16-fold more potent than that of CMA-676 illustrating the therapeutic advantage with specifically targeted chemotherapy.
The B-lymphoid lineage-specific molecule CD22, the target of CMC-544, is a member of the Siglec family of molecules (Siglec-2) capable of recognizing terminal a2-6-linked sialic acid residues on glycoproteins or glycolipids. 24 CD33, a myeloid lineage-specific molecule, is also a member of the Siglec family (Siglec-3) and recognizes a2-3-linked terminal sialic acid residues. 25 In a study by Gudowius et al. 15 , involving 181 ALL patients, CD22 was shown to be expressed on the surface of 490% of leukemic blasts in a vast majority of ALL patients. Similar expression of CD22 on ALL blasts was also reported by Boue and Lebien. 26 In contrast, only 18% of the ALL patients were reported to express CD33 on the leukemic blasts. 22, 27, 28 Patients with CD33 þ ALL responded favorably to the treatment with gemtuzumab ozogamicin. 22, 28, 29 In a pediatric study conducted in conjunction with gemtuzumab ozogamicin, leukemic blast cells from two patients (55% blasts from one and 88% blasts from the other) were shown to express on their surface both CD22 and CD33. 22 Given the sensitivity of ALL cells to calicheamicin and potential to express CD22 and CD33, either simultaneous or sequential use of inotuzumab ozogamicin and gemtuzumab ozogamicin may confer greater therapeutic advantage by targeting both CD22 þ and CD33 þ ALL cells.
In the present study, CMC-544 caused regression of established subcutaneous ALL xenografts and also protected against systemically disseminated ALL capable of invading the CNS producing hind-limb paralysis. These observations point to the ability of CMC-544 to target ALL cells in otherwise immunologically privileged organ systems such as the CNS. These results are consistent with our previous preclinical observations demonstrating strong protective activity of CMC-544 against systemically disseminated B-cell lymphoma. 12 Invasion of ALL cells into the CNS presents a major clinical challenge in patients with relapsed ALL. Conventional chemotherapy is often therapeutically unsatisfactory against such a state of the disseminated disease. Targeted chemotherapeutics such as CMC-544 may be more beneficial than conventional chemotherapy in treating leukemia or lymphoma patients with disseminated disease.
Taken together, results described in this study provide the necessary preclinical basis and support for clinical evaluation of inotuzumab ozogamicin (CMC-544) in patients with ALL. CMC-544 may represent an important therapeutic option for the treatment of patients with CD22 þ ALL.
